Raras
Buscar doenças, sintomas, genes...
Síndrome C-like
ORPHA:97297CID-10 · Q87.8OMIM 605039DOENÇA RARA

A síndrome de Bohring-Opitz é uma condição rara caracterizada por: * **Crescimento deficiente no útero (IUGR):** o bebê não cresce o suficiente ainda dentro da barriga da mãe. * **Dificuldade para se desenvolver e ganhar peso** após o nascimento. * **Características faciais peculiares,** que incluem: uma linha bem visível na testa (sutura metópica proeminente); uma mancha de nascença avermelhada na testa (nevus flammeus ou "mancha de vinho do porto"); cabelos que nascem muito baixos na testa e nas têmporas, com excesso de pelos (hirsutismo); bochechas cheinhas/inchadas; olhos com o canto externo voltado para cima; olhos um pouco saltados (exoftalmia); olhos mais espaçados do que o normal (hipertelorismo); lábio leporino e fenda no céu da boca; queixo pequeno e para trás (retrognatia); e orelhas em uma posição mais baixa que o comum. * **Deformidades nos cotovelos e punhos,** que ficam curvados. * **Dedos curvados de forma permanente** (camptodactilia). * **Dedos das mãos desviados** para o lado do dedo mínimo (desvio ulnar). * **Alterações nos pés.** * **Atraso grave no desenvolvimento global.** Até o momento, menos de 20 pacientes com essa síndrome foram descritos na literatura médica. Apesar de a maioria dos casos relatados ter surgido de forma isolada (sem uma causa genética clara ou sem que houvesse outros casos na família), também foram registrados casos onde a doença é herdada dos pais de forma recessiva (quando ambos os pais são portadores do gene, mas não manifestam a doença).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A síndrome de Bohring-Opitz é uma condição rara caracterizada por: * **Crescimento deficiente no útero (IUGR):** o bebê não cresce o suficiente ainda dentro da barriga da mãe. * **Dificuldade para se desenvolver e ganhar peso** após o nascimento. * **Características faciais peculiares,** que incluem: uma linha bem visível na testa (sutura metópica proeminente); uma mancha de nascença avermelhada na testa (nevus flammeus ou "mancha de vinho do porto"); cabelos que nascem muito baixos na testa e nas têmporas, com excesso de pelos (hirsutismo); bochechas cheinhas/inchadas; olhos com o canto externo voltado para cima; olhos um pouco saltados (exoftalmia); olhos mais espaçados do que o normal (hipertelorismo); lábio leporino e fenda no céu da boca; queixo pequeno e para trás (retrognatia); e orelhas em uma posição mais baixa que o comum. * **Deformidades nos cotovelos e punhos,** que ficam curvados. * **Dedos curvados de forma permanente** (camptodactilia). * **Dedos das mãos desviados** para o lado do dedo mínimo (desvio ulnar). * **Alterações nos pés.** * **Atraso grave no desenvolvimento global.** Até o momento, menos de 20 pacientes com essa síndrome foram descritos na literatura médica. Apesar de a maioria dos casos relatados ter surgido de forma isolada (sem uma causa genética clara ou sem que houvesse outros casos na família), também foram registrados casos onde a doença é herdada dos pais de forma recessiva (quando ambos os pais são portadores do gene, mas não manifestam a doença).

Pesquisas ativas
2 ensaios
2 total registrados no ClinicalTrials.gov
Publicações científicas
68 artigos
Último publicado: 2026 Feb 12

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
46
pacientes catalogados
Início
Antenatal
+ neonatal
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: Q87.8
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (5)
0202010503
Cariótipo — bandas G, Q ou Rgenetic_test
0202010600
Pesquisa de microdeleções/microduplicações por FISHlab_test
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202010260
Dosagem de alfa-fetoproteína
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

😀
Face
17 sintomas
🦴
Ossos e articulações
11 sintomas
🧠
Neurológico
11 sintomas
👁️
Olhos
8 sintomas
❤️
Coração
6 sintomas
🫃
Digestivo
5 sintomas

+ 35 sintomas em outras categorias

Características mais comuns

100%prev.
HP:0003577
Frequência: 7/7
100%prev.
Dificuldades alimentares
Frequência: 6/6
100%prev.
Déficit de crescimento
Frequência: 6/6
100%prev.
Deficiência intelectual, profunda
Frequente (79-30%)
100%prev.
Proptose
Frequente (79-30%)
100%prev.
Microcefalia
Frequente (79-30%)
116sintomas
Muito frequente (16)
Frequente (44)
Ocasional (20)
Muito raro (6)
Sem dados (30)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 116 características clínicas mais associadas, ordenadas por frequência.

HP:0003577
Frequência: 7/7100%
Dificuldades alimentaresFeeding difficulties
Frequência: 6/6100%
Déficit de crescimentoFailure to thrive
Frequência: 6/6100%
Deficiência intelectual, profundaIntellectual disability, profound
Frequente (79-30%)100%
ProptoseProptosis
Frequente (79-30%)100%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico68PubMed
Últimos 10 anos50publicações
Pico20176 papers
Linha do tempo
2026Hoje · 2026🧪 2010Primeiro ensaio clínico📈 2017Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant.

ASXL1Polycomb group protein ASXL1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable Polycomb group (PcG) protein involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor gamma (PPARG) (PubMed:16606617). Acts as a coactivator of RARA and RXRA through association with NCOA1 (PubMed:16606617). Acts as a corepressor for PPARG and suppresses its adipocyte differentiation-inducing activity (By similarity). Non-catalytic component of the PR-DUB complex, a co

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
UCH proteinases
MECANISMO DE DOENÇA

Bohring-Opitz syndrome

A syndrome characterized by severe intrauterine growth retardation, poor feeding, profound intellectual disability, trigonocephaly, prominent metopic suture, exophthalmos, nevus flammeus of the face, upslanting palpebral fissures, hirsutism, and flexion of the elbows and wrists with deviation of the wrists and metacarpophalangeal joints.

VIAS REACTOME (1)
OUTRAS DOENÇAS (6)
myelodysplastic syndromeBohring-Opitz syndromeaggressive systemic mastocytosisacute myeloid leukemia with multilineage dysplasia
HGNC:18318UniProt:Q8IXJ9

Variantes genéticas (ClinVar)

262 variantes patogênicas registradas no ClinVar.

🧬 ASXL1: NM_015338.6(ASXL1):c.1748G>A (p.Trp583Ter) ()
🧬 ASXL1: NM_015338.6(ASXL1):c.3675A>C (p.Lys1225Asn) ()
🧬 ASXL1: NM_015338.6(ASXL1):c.1204C>T (p.Arg402Ter) ()
🧬 ASXL1: GRCh37/hg19 20q11.21-13.12(chr20:31010829-44560369)x1 ()
🧬 ASXL1: NM_015338.6(ASXL1):c.1129C>T (p.Gln377Ter) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 170 variantes classificadas pelo ClinVar.

153
17
Patogênica (90.0%)
VUS (10.0%)
VARIANTES MAIS SIGNIFICATIVAS
ASXL1: NM_015338.6(ASXL1):c.3416del (p.Thr1139fs) [Likely pathogenic]
ASXL1: NM_015338.6(ASXL1):c.1926del (p.Gly645fs) [Likely pathogenic]
ASXL1: NM_015338.6(ASXL1):c.2182del (p.Glu728fs) [Likely pathogenic]
ASXL1: NM_015338.6(ASXL1):c.3751C>T (p.Gln1251Ter) [Likely pathogenic]
ASXL1: NM_015338.6(ASXL1):c.2242C>T (p.Gln748Ter) [Likely pathogenic]

Vias biológicas (Reactome)

1 via biológica associada aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 2 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome C-like

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
51 papers (10 anos)
#1

Reassessing Benign ASXL1 Variants in Bohring-Opitz Syndrome: The Role of Population Databases in Variant Reinterpretation.

Genes2026 Feb 12

Background/Objectives: ASXL1 is a chromatin-associated gene implicated in both hematologic malignancies and neurodevelopmental disorders, including Bohring-Opitz syndrome (BOS). Although many ASXL1 variants are well classified, a substantial proportion remain variants of uncertain significance (VUS), complicating molecular diagnosis and genetic counseling. The objective of this study was to evaluate whether structural context can inform the interpretation of selected ASXL1 missense variants in a clinical setting. Methods: We describe a 17-year-old female with clinical features consistent with BOS carrying the heterozygous ASXL1 variant p.Q1448R, currently classified as benign under ACMG/AMP guidelines. Three-dimensional in silico structural modeling was performed using AlphaFold3 and available crystallographic data. Three additional ASXL1 missense variants classified as VUS in ClinVar (p.R265H, p.T297M, and p.Y358C) were also analyzed. Evolutionary conservation, domain localization, and residue-level interactions were assessed. Results: Structural modeling indicated that the p.Q1448R substitution alters polar interactions and introduces a steric constraint near a conserved PHD-type zinc finger domain. Variants p.R265H and p.T297M affected stabilizing interactions within the DEUBAD, which is involved in BAP1 activation, while p.Y358C altered a polar microenvironment adjacent to a chromatin-interacting region. All analyzed variants, except p.T297M, localized to evolutionarily conserved regions. Conclusions: This study demonstrates that in silico structural analysis can provide complementary, domain-level insights for the interpretation of ASXL1 missense variants that remain classified as benign, likely benign or VUS under current frameworks. Such approaches may assist in prioritizing variants for further functional evaluation and refining molecular interpretation when experimental data are limited.

#2

Assessing Pubertal Timing, Duration, and Related Characteristics in ASXL-Related Disorders: A Cross-Sectional Caregiver Survey Analysis.

American journal of medical genetics. Part A2026 Jan

Limited studies have been conducted on pubertal development in populations with pre-existing medical conditions. More than 20-fold increased risk of early puberty has been reported in neurodevelopmental disorders; however, this is a heterogeneous group. There have been limited past studies examining the timing, duration, or characteristics of pubertal or menstrual cycle development in patients with ASXL-related disorders. This study aimed to gather empirical cross-sectional parent survey data regarding pubertal development in adolescents diagnosed with Bohring-Opitz syndrome (BOS) (ASXL1), Shashi-Pena syndrome (SPS) (ASXL2), or Bainbridge-Ropers syndrome (BRS) (ASXL3). Our findings showed evidence for parental and perceived provider concern for premature pubarche and possible precocious puberty (PP) in BOS (ASXL1) males and females. Findings between the BOS (ASXL1) and BRS (ASXL3) individuals differed, representing distinct pubertal phenotypes within these populations. Notable trends toward premature development may warrant a low threshold for pediatric endocrinological evaluation in this population. The characterization and description of a pubertal profile for the ASXL-related syndromes can help inform providers and parents when navigating this stage of development. Our study findings also highlight the need for prospective natural history studies to further define the contribution of pubertal development to the ASXL disorders phenotypes.

#3

Asxl1 loss in mice leads to microcephaly by regulating neural stem cell survival.

Animal cells and systems2025

Additional sex comb-like 1 (ASXL1) is a chromatin-associated factor essential for transcriptional regulation. De novo truncating mutations in the ASXL1 gene are linked to Bohring-Opitz syndrome, a developmental disorder characterized by microcephaly; however, the role of Asxl1 in brain development remains unclear. In this study, we demonstrate that Asxl1 deletion in mice induces microcephaly, primarily caused by a reduction in the size and number of cortical neurons. Asxl1 ablation disrupts neural stem cell (NSC) maintenance, as evidenced by decreased proliferation and increased apoptosis. Transcriptomic analysis of Asxl1-deficient NSCs revealed 4,635 differentially expressed genes, including 2,262 upregulated and 2,373 downregulated genes. Gene ontology analysis indicated that Asxl1 regulates NSC survival through the histone methyltransferase Ezh2, a core component of the Polycomb Repressive Complex 2 (PRC2). Inhibition of H3K27me3 using GSK343 significantly reduced the viability of wild-type NSCs, but had a markedly diminished effect on Asxl1-deficient NSCs. Furthermore, Ezh2 target genes associated with apoptosis, such as Epha7 and Osr1, were upregulated in wild-type NSCs following GSK343 treatment but not significantly affected in Asxl1-deficient NSCs. These findings establish Asxl1 as a critical regulator of NSC survival and neurogenesis via Ezh2-mediated chromatin modification and provide insights into the mechanisms underlying microcephaly in developmental disorders.

#4

ASXL1 deficiency causes epigenetic dysfunction, combined immunodeficiency, and EBV-associated lymphoma.

The Journal of experimental medicine2025 Oct 06

Inborn errors of immunity (IEIs) are caused by deleterious variants in immune-related genes. ASXL1 is an epigenetic modifier not previously linked to an IEI. Clonal hematopoiesis and hematologic neoplasms often feature somatic ASXL1 variants, and Bohring-Opitz syndrome, a neurodevelopmental disorder, is caused by heterozygous truncating ASXL1 variants. We present an IEI caused by biallelic germline missense variants in ASXL1. The patient had a history of hematologic abnormalities and viral-associated complications, including chronic macrocytosis, persistent vaccine-strain rubella granulomas, and EBV-associated Hodgkin lymphoma. Immunophenotyping revealed loss of B cells, hypogammaglobulinemia, and impairments in cytotoxic T and NK cell populations. T cells exhibited skewing toward an exhausted memory phenotype, global DNA methylation loss, and increased epigenetic aging. These aberrations were ameliorated by wild-type ASXL1 transduction, confirming the patient variants' pathogenicity. This study defines a novel human IEI caused by ASXL1 deficiency, a diagnosis that should be considered in individuals with chronic viral infections, viral-associated malignancies, and combined immune deficiency.

#5

Bohring-Opitz syndrome: Unraveling neonatal hypoglycemia and early detection through whole exome sequencing.

Pediatrics and neonatology2024 Nov

Publicações recentes

Ver todas no PubMed

📚 EuropePMC37 artigos no totalmostrando 50

2026

Reassessing Benign ASXL1 Variants in Bohring-Opitz Syndrome: The Role of Population Databases in Variant Reinterpretation.

Genes
2026

Assessing Pubertal Timing, Duration, and Related Characteristics in ASXL-Related Disorders: A Cross-Sectional Caregiver Survey Analysis.

American journal of medical genetics. Part A
2025

ASXL1 deficiency causes epigenetic dysfunction, combined immunodeficiency, and EBV-associated lymphoma.

The Journal of experimental medicine
2025

Asxl1 loss in mice leads to microcephaly by regulating neural stem cell survival.

Animal cells and systems
2024

ASXL1 truncating variants in BOS and myeloid leukemia drive shared disruption of Wnt-signaling pathways but have differential isoform usage of RUNX3.

BMC medical genomics
2024

Role of Nasopharyngeal Airway in Management of Craniofacial Syndrome-Associated Upper Airway Obstruction in Children.

Orthodontics &amp; craniofacial research
2024

ASXL1-related Bohring-Optiz syndrome complicated by persistent neonatal pulmonary hypertension and abnormal alveoli formation.

European journal of medical genetics
2024

Bohring-Opitz syndrome: Unraveling neonatal hypoglycemia and early detection through whole exome sequencing.

Pediatrics and neonatology
2024

Two cases of hepatoblastoma in Bohring-Opitz syndrome: An emerging association.

Pediatric blood &amp; cancer
2024

Perthes-Like Disorder in a Child with Atypical Bohring-Opitz Syndrome.

JBJS case connector
2023

Examining the neurodevelopmental and motor phenotypes of Bohring-Opitz syndrome (ASXL1) and Bainbridge-Ropers syndrome (ASXL3).

Frontiers in neuroscience
2023

Multiomics of Bohring-Opitz syndrome truncating ASXL1 mutations identify canonical and noncanonical Wnt signaling dysregulation.

JCI insight
2023

Clinical findings in 39 individuals with Bohring-Opitz syndrome from a global patient-driven registry with implications for tumor surveillance and recurrence risk.

American journal of medical genetics. Part A
2022

Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720-2A>G variant.

Journal of clinical laboratory analysis
2022

DNA methylation signature associated with Bohring-Opitz syndrome: a new tool for functional classification of variants in ASXL genes.

European journal of human genetics : EJHG
2022

De novo nonsense variant in ASXL3 in a Chinese girl causing Bainbridge-Ropers syndrome: A case report and review of literature.

Molecular genetics &amp; genomic medicine
2022

Bohring-Opitz syndrome caused by a novel ASXL1 mutation (c.3762delT) in an IVF baby: A case report.

Medicine
2021

A de novo Variant of ASXL1 Is Associated With an Atypical Phenotype of Bohring-Opitz Syndrome: Case Report and Literature Review.

Frontiers in pediatrics
2021

Self-Induced Bilateral Retinal Detachments and Traumatic Cataracts in a Patient With Bohring-Opitz Syndrome.

Ophthalmic surgery, lasers &amp; imaging retina
2021

Anaesthesia and orphan diseases: Bohring-Opitz syndrome.

European journal of anaesthesiology
2021

Understanding the phenotypic spectrum of ASXL-related disease: Ten cases and a review of the literature.

American journal of medical genetics. Part A
2021

Novel truncating mutations in ASXL1 identified in two boys with Bohring-Opitz syndrome.

European journal of medical genetics
2021

Further expanding the clinical phenotype in Bainbridge-Ropers syndrome and dissecting genotype-phenotype correlation in the ASXL3 mutational cluster regions.

European journal of medical genetics
2020

The tale of two genes: from next-generation sequencing to phenotype.

Cold Spring Harbor molecular case studies
2020

A novel PTC mutation in the BTB domain of KLHL7 gene in two patients with Bohring-Opitz syndrome-like features.

European journal of medical genetics
2019

A de novo truncating mutation in ASXL1 associated with segmental overgrowth.

Journal of genetics
2020

Extending the phenotypic spectrum of Bohring-Opitz syndrome: Mild case confirmed by functional studies.

American journal of medical genetics. Part A
2019

Double outlet right ventricle and aortopulmonary window in a neonate with Bohring-Opitz (Oberklaid-Danks) syndrome: First case report.

Journal of family medicine and primary care
2019

Pathological ASXL1 Mutations and Protein Variants Impair Neural Crest Development.

Stem cell reports
2019

New macular findings in individuals with biallelic KLHL7 gene mutation.

BMJ open ophthalmology
2019

Two siblings with a novel nonsense variant provide further delineation of the spectrum of recessive KLHL7 diseases.

European journal of medical genetics
2018

The ASXL1 mutation p.Gly646Trpfs*12 found in a Turkish boy with Bohring-Opitz Syndrome.

Clinical case reports
2018

Lethal persistent pulmonary hypertension of the newborn in Bohring-Opitz syndrome.

American journal of medical genetics. Part A
2018

Bohring-Opitz syndrome caused by an ASXL1 mutation inherited from a germline mosaic mother.

American journal of medical genetics. Part A
2018

Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates.

Cell discovery
2018

A de novo nonsense mutation in ASXL3 shared by siblings with Bainbridge-Ropers syndrome.

Cold Spring Harbor molecular case studies
2017

Syndromic Craniosynostosis Can Define New Candidate Genes for Suture Development or Result from the Non-specifc Effects of Pleiotropic Genes: Rasopathies and Chromatinopathies as Examples.

Frontiers in neuroscience
2017

Expanding the clinical spectrum of recessive truncating mutations of KLHL7 to a Bohring-Opitz-like phenotype.

Journal of medical genetics
2017

ASXL gain-of-function truncation mutants: defective and dysregulated forms of a natural ribosomal frameshifting product?

Biology direct
2017

Bohring-opitz syndrome - A case of a rare genetic disorder.

The Medical journal of Malaysia
2017

Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome.

Human mutation
2017

Bainbridge-Ropers syndrome caused by loss-of-function variants in ASXL3: a recognizable condition.

European journal of human genetics : EJHG
2016

Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice.

Stem cell reports
2016

Novel splicing mutation in the ASXL3 gene causing Bainbridge-Ropers syndrome.

American journal of medical genetics. Part A
2016

A novel de-novo frameshift mutation of the ASXL1 gene in a classic case of Bohring-Opitz syndrome.

Clinical dysmorphology
2016

Screening of CD96 and ASXL1 in 11 patients with Opitz C or Bohring-Opitz syndromes.

American journal of medical genetics. Part A
2015

Penetrance of pathogenic mutations in haploinsufficient genes for intellectual disability and related disorders.

European journal of medical genetics
2015

Bohring-Opitz syndrome (BOS) with a new ASXL1 pathogenic variant: Review of the most prevalent molecular and phenotypic features of the syndrome.

American journal of medical genetics. Part A
2015

Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.

Nature communications
2015

Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance.

American journal of medical genetics. Part A

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome C-like.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome C-like

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Reassessing Benign ASXL1 Variants in Bohring-Opitz Syndrome: The Role of Population Databases in Variant Reinterpretation.
    Genes· 2026· PMID 41751615mais citado
  2. Assessing Pubertal Timing, Duration, and Related Characteristics in ASXL-Related Disorders: A Cross-Sectional Caregiver Survey Analysis.
    American journal of medical genetics. Part A· 2026· PMID 40808361mais citado
  3. Asxl1 loss in mice leads to microcephaly by regulating neural stem cell survival.
    Animal cells and systems· 2025· PMID 40276524mais citado
  4. ASXL1 deficiency causes epigenetic dysfunction, combined immunodeficiency, and EBV-associated lymphoma.
    The Journal of experimental medicine· 2025· PMID 40742536mais citado
  5. Bohring-Opitz syndrome: Unraveling neonatal hypoglycemia and early detection through whole exome sequencing.
    Pediatrics and neonatology· 2024· PMID 39098553mais citado
  6. ASXL1 truncating variants in BOS and myeloid leukemia drive shared disruption of Wnt-signaling pathways but have differential isoform usage of RUNX3.
    BMC Med Genomics· 2024· PMID 39614348recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:97297(Orphanet)
  2. OMIM OMIM:605039(OMIM)
  3. MONDO:0011510(MONDO)
  4. GARD:10140(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q4938225(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome C-like
Compêndio · Raras BR

Síndrome C-like

ORPHA:97297 · MONDO:0011510
Prevalência
<1 / 1 000 000
Casos
46 casos conhecidos
Herança
Autosomal dominant
CID-10
Q87.8 · Outras síndromes com malformações congênitas especificadas, não classificadas em outra parte
Ensaios
2 ativos
Início
Antenatal, Neonatal
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0796232
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades